STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBDDan Turner, Axel Dignaß, Amanda Ricciuto et al.|Gastroenterology|2021Cited by 2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-TargetLaurent Peyrin‐Biroulet, Shawn Winer, Stephen B. Hanauer et al.|The American Journal of Gastroenterology|2015Cited by 1.8k
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D’Haens, Marc Ferrante, Remo Panaccione et al.|The Lancet|2022Cited by 383
Extraintestinal manifestations in inflammatory bowel diseaseSilvio Danese|World Journal of Gastroenterology|2005Cited by 374
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic ResectionMiguel Regueiro, Pierre Desreumaux, Brian G. Feagan et al.|Gastroenterology|2016Cited by 329